Core Insights - Opko Health Inc. (NASDAQ:OPK) is identified as one of the best stocks under $5 with significant upside potential [1] - ModeX Therapeutics Inc., a subsidiary of Opko Health, has entered into a collaboration with Regeneron Pharmaceuticals for the development of multispecific antibodies [2] Collaboration Agreement - The agreement includes an upfront payment of USD $7 million to ModeX, with potential future payments exceeding USD $200 million per selected molecule [3] - The overall value of the collaboration could exceed $1 billion if multiple products are successful, with ModeX also eligible for tiered global net sales royalties [4] Company Overview - Opko Health Inc. operates in the biopharmaceutical and diagnostics sectors, providing healthcare services through its Diagnostics and Pharmaceuticals segments [5]